Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-Month Phase 3 Multicenter Placebo-Controlled Study of Solanezumab in Prodromal Alzheimer's Disease
2016-000108-27Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Solanezumab 400 mg with Placebo (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score. Started Jun 2016; status: terminated.
02
Drugs
solanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2016-000108-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000108-27.